Member Info for GeneralOz

This is not a merry situation for Avacta holders, from this we can draw 2 conclusions:

1) Not enough retail interest. Retail investors have almost given up on this company and they couldn’t raise enough capital from them. Not good for the future raises!

2) The BOD had an agreement with institutions and forward sellers to limit retail buyers. They know retail buyers will buy stock from institutions that took part in the placing at a higher price. Hence the importance of limiting stock to retail investors in favour of the old boys.

And now the RNS, well even Alastairs wording doesn’t make much sense. I imagine there will be a lot of selling to come after that.

NYsize must've got the spreadsheets mixed up again.

Yes the BOD will agree (they may have done so already) to raise above £6.8 million. Part of the rational for the discount, as agreed by the BOD was for them to raise as much capital as possible in this placing. With the underlying CLN ripping away it is completely within the interest of the BOD and company to do this. In the slim chance they don't, when they come to the next placing in 18 months at 20p, they'll get criticised for not taking enough at 50p.

The real kick in the face to PIs when it comes to the dual listing, is that it's not in the interest for the BOD to list on Nasdaq as there is more oversight than AIM. Hence they wouldn't be able to get away with misleading PIs. Everyone thought the placing in 2020 would've been the last on AIM due to all of the insider trading. 4 years later, here we are.

B2, it has already been established that the REX will go above £6.8 million. The BOD will take as much money as possible as they regonise any fundraise in the future will be very difficult due to the discount they ran this one at. Terms of the CLN will ensure that the company can stay afloat long enough to cover the CLN in shares. Even the timelines for their clinical trails have been extended so cash burn is reduced prior to this date.

The placing has been done at 50p Timster. Of course it was going to oversubscribed when it previously traded over 100p.

Perhaps they'll do the next placing at 70-80p?

Was the FDA involved in the LFT design?

There's the proof we needed folks. NYsize sold his own stock ahead of the placing because he believes everything he reads on the internet.

It's a therapeutics pure play then. Hope it doesn't fail?

Really doing your best rub salt in the wound for those blindsided by this raise, Bella. According to you, this is how PIs deserve to be treated when investing in this company. In

So you are able to short the stock! Perhaps when Sheppy meets you, you can teach him how to hedge?

I didn't know you could short this stock, NYsize. Maybe you could tell everyone how to do it?

Tom Winnifrith (TW) has predicted every single Avacta placing since 2020. Hence anyone who predicts a placing now works for him, apparently. Difference is, TW makes his calls using inside information instead of logic.

Weird how NYsize loathes him so much.

Let’s do some navel gazing, seeing as you brought up posting history Flip.

Cash runs out by H2 2024, if you knew how to read a balance sheet, that was obvious. The company did the right thing by trying to raise in June 2023 as the market knew their runway was strong, hence a stronger negotiating position. For a reason, which was ‘not disclosed’ to the public market they couldn’t raise enough. So by end of year, it was pretty obvious they’d have to raise and the raise would have to be done after the conversion in January.

Still believe those predicting a raise were ‘FUDSTERS’?

“you need to change your identity yet again.”

Is that something you’re familiar with doing Flip?

"£20 a share.. you guys are thinking too small."

How about 20p a share? Well, you're thinking too high.

It works during phase 1, hartyh. Phase 2? Phase 3? Who knows.

It works until it doesn't.

Until it doesn't.

"his bullishness and obviously false misleading comments"

What comments are you referring to exactly? Precision works. Until it doesn't.